A New Collaboration Could Be Key in the Early Detection of Lung Cancer

A newly-formed partnership between Biodesix and MRM Proteomics could be the key that unlocks the door for better outcomes in lung cancer patients. Earlier this week, the two diagnostic companies announced a deal that would have Montreal-based MRM Proteomics granting Biodesix the rights to use the iMALDI technologies. Boulder, CO-based Biodesix would use iMALDI to further advance its blood-based lung cancer diagnostics. “MRM has long been a leader in developing new tools in proteomics,” David Brunel CEO of Biodesix, told MD+DI. “A partnership with [MRM] allows us to expand the set of tools we use to probe the biology and answer the complex questions.” MRM has existing assays that Biodesix will incorporate into its laboratories in a CLIA setting. That should happen in the next half year. An FDA-approved product would probably be available two-to-four years out – depending on regulatory and reimbursement requirements. “Examining a patient’s genomic data has advanced targeted therapies. However, proteins are the targets of most drugs and hold the key to unlocking the promise of precision medicine,” Christoph Borchers, CSO for MRM Proteomics said in a release. “Biodesix is a natural partner for our proteomic technology, because they are committed to a multi-omics approach to reveal a more complete molecular profile of lun...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news